LY4584180 Clinical Trials (2026): 1 Studies for Follicular Lymphoma & Lymphoma, Diffuse Large B-Cell
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 LY4584180 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Follicular Lymphoma & Lymphoma, Diffuse Large B-Cell) and 460 total planned enrollment. 1 LY4584180 clinical trial is actively recruiting at 13 U.S. sites across 10 states. Most recent activity: NCT07226843 (Feb 2030).
Where to Participate: All LY4584180 Trial Sites in the U.S. (13 sites across 10 states)
Every actively recruiting LY4584180trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope | Duarte91010 | NCT07226843 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT07226843 | Map |
| FL | Florida Cancer Specialists - Sarasota | Sarasota34236 | NCT07226843 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT07226843 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07226843 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07226843 | Map |
| NY | Columbia University | New York10032 | NCT07226843 | Map |
| NY | University of Rochester | Rochester14618 | NCT07226843 | Map |
| OH | The Ohio State University (OSU) | Columbus43210 | NCT07226843 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT07226843 | Map |
| TN | Vanderbilt University Medical Center | Nashville37212 | NCT07226843 | Map |
| TX | Texas Oncology - DFW (Sammons CC) | Dallas75246 | NCT07226843 | Map |
| WA | University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance) | Seattle98195 | NCT07226843 | Map |
LY4584180 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting LY4584180 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | P1 | Lymphoma, Non-Hodgkin's | 460 | Apr 2026 |
All LY4584180 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | P1 | recruiting | 460 | Eli Lilly and Company | Apr 2026 |
LY4584180 clinical trials: frequently asked questions
- How many LY4584180 clinical trials are there?
- 1 LY4584180 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are LY4584180 clinical trials recruiting in 2026?
- Yes — 1 LY4584180 trial is actively recruiting in 2026, with 13 U.S. sites across 10 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4584180 being studied for?
- LY4584180 is being studied for Follicular Lymphoma, Lymphoma, Diffuse Large B-Cell, Lymphoma, Non-Hodgkin's. The trials are grouped by indication on this page.
- What phase is LY4584180 in?
- LY4584180 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4584180 clinical trials?
- The lead sponsor across the most LY4584180 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4584180as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: